Kathleen Schostack
Overview
Explore the profile of Kathleen Schostack including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
390
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dienstmann R, Lassen U, Cebon J, Desai J, Brown M, Evers S, et al.
Target Oncol
. 2015 Aug;
11(2):149-56.
PMID: 26310975
Background: BRAF mutations are a validated target for cancer therapy. A second-generation BRAF inhibitor with an improved preclinical safety profile (RG7256) was evaluated in a first-in-man study in order to...
2.
Yin X, Luistro L, Zhong H, Smith M, Nevins T, Schostack K, et al.
Clin Cancer Res
. 2013 Aug;
19(20):5686-98.
PMID: 23974006
Purpose: To explore the role of TWEAK in tumor growth and antitumor immune response and the activity and mechanism of RG7212, an antagonistic anti-TWEAK antibody, in tumor models. Experimental Design:...
3.
Su F, Bradley W, Wang Q, Yang H, Xu L, Higgins B, et al.
Cancer Res
. 2011 Dec;
72(4):969-78.
PMID: 22205714
A high percentage of patients with BRAF(V600E) mutant melanomas respond to the selective RAF inhibitor vemurafenib (RG7204, PLX4032) but resistance eventually emerges. To better understand the mechanisms of resistance, we...
4.
Yang H, Higgins B, Kolinsky K, Packman K, Bradley W, Lee R, et al.
Cancer Res
. 2011 Dec;
72(3):779-89.
PMID: 22180495
The protein kinase BRAF is a key component of the RAS-RAF signaling pathway which plays an important role in regulating cell proliferation, differentiation, and survival. Mutations in BRAF at codon...
5.
Yang H, Higgins B, Kolinsky K, Packman K, Go Z, Iyer R, et al.
Cancer Res
. 2010 Jun;
70(13):5518-27.
PMID: 20551065
The BRAF(V600E) mutation is common in several human cancers, especially melanoma. RG7204 (PLX4032) is a small-molecule inhibitor of BRAF(V600E) kinase activity that is in phase II and phase III clinical...